elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Olaparib
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Olaparib
RIS
0.003
(Research Intensity Score)
Papers
318
Top papers
Pancreatic Cancer
2021 · 1892 citations
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
2024 · 357 citations
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
2019 · 2231 citations
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
2018 · 2874 citations
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
2022 · 268 citations
Newest papers
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial
2026 · 6 citations
Real-world outcomes following PARP inhibitor maintenance in ovarian cancer by BRCA status: a retrospective cohort study
2026 · 2 citations
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
2025 · 49 citations
Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance
2025 · 21 citations
177 Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial
2025 · 21 citations
A sample from the 100 top papers behind Olaparib.
Create a free account to browse them all →
Olaparib's history
Research intensity over time
Explore Olaparib's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Olaparib's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link